Harshman, L. C., Puligandla, M., Haas, N. B., Drake, C. G., McDermott, D. F., Signoretti, S., … Allaf, M. (2018). PROSPER: A phase III randomized study comparing perioperative nivolumab (nivo) vs. observation in patients with localized renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN 8143). In Journal of Clinical Oncology (Vol. 36, pp. TPS4597–TPS4597). American Society of Clinical Oncology (ASCO). https://doi.org/10.1200/jco.2018.36.15_suppl.tps4597

Harshman, Lauren Christine, Maneka Puligandla, Naomi B. Haas, Charles G. Drake, David F. McDermott, Sabina Signoretti, David Cella, et al. “PROSPER: A phase III randomized study comparing perioperative nivolumab (nivo) vs. observation in patients with localized renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN 8143).” In Journal of Clinical Oncology, 36:TPS4597–TPS4597. American Society of Clinical Oncology (ASCO), 2018. https://doi.org/10.1200/jco.2018.36.15_suppl.tps4597.

Harshman LC, Puligandla M, Haas NB, Drake CG, McDermott DF, Signoretti S, et al. PROSPER: A phase III randomized study comparing perioperative nivolumab (nivo) vs. observation in patients with localized renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN 8143). In: Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2018. p. TPS4597–TPS4597.

Harshman, Lauren Christine, et al. “PROSPER: A phase III randomized study comparing perioperative nivolumab (nivo) vs. observation in patients with localized renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN 8143).” Journal of Clinical Oncology, vol. 36, no. 15_suppl, American Society of Clinical Oncology (ASCO), 2018, pp. TPS4597–TPS4597. Crossref, doi:10.1200/jco.2018.36.15_suppl.tps4597.

Harshman LC, Puligandla M, Haas NB, Drake CG, McDermott DF, Signoretti S, Cella D, Gupta RT, Wagner LI, Shuch BM, Lara P, Choueiri TK, Kapoor A, Heng DYC, Michaelson MD, Jewett MAS, Van Allen EM, George DJ, Carducci MA, Allaf M. PROSPER: A phase III randomized study comparing perioperative nivolumab (nivo) vs. observation in patients with localized renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN 8143). Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2018. p. TPS4597–TPS4597.